Cullinan Therapeutics, Inc.

CGEM · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$50,610-$70,055-$48,501-$47,647
Dep. & Amort.$79$77$76$77
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$9,887$9,374$9,634
Change in WC$5,545$4,188-$1,793$4,821
Other Non-Cash$8,109-$1,706-$2,311-$3,511
Operating Cash Flow-$36,877-$57,609-$43,155-$36,626
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$12,570-$78,526-$125,840-$168,036
Inv. Sales/Matur.$80,000$131,927$162,645$184,000
Other Inv. Act.-$38$0$0$0
Investing Cash Flow$67,392$53,401$36,805$15,964
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$1,582
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$373$0$0
Financing Cash Flow$0$373$0$1,582
Forex Effect$0$0$0$0
Net Chg. in Cash$30,515-$3,835-$6,350-$19,080
Supplemental Information
Beg. Cash$72,820$76,655$83,005$102,085
End Cash$103,335$72,820$76,655$83,005
Free Cash Flow$0-$57,609-$43,155-$36,626
Cullinan Therapeutics, Inc. (CGEM) Financial Statements & Key Stats | AlphaPilot